COVID-19: Vaccines on Their Marks



DOI: 10.36664/bt/2021/v68i1/162888


Ekta Jagtiani 1*, Darsh Vithlani 2

Abstract:

Vaccine-derived immunity is being optimistically heralded as the exit strategy to the pandemic, thereby enabling everyone to return to the much-awaited normal patterns of working, schooling, and socialising. The SARS-COV-2 (COVID-19) respiratory virus was first identified in December 2019 in Wuhan, China. Owing to the rampant spread of the virus there was an exigency that called for the development of a vaccine. In this review, we discuss what is currently known about the mechanism of action, efficacy, safety profile, clinical trials, and distribution of three of the most promising vaccine candidates; mRNA-1273 (Moderna), BNT162b2 (Pfizer/BioNtech), ChAdOx1 nCoV-19 (AstraZeneca/Oxford). In the race to come up with a safe and effective vaccine against the novel coronavirus, there are a myriad of factors that play a critical role throughout the development, clinical trials, manufacturing, distribution phases. An in-depth insight is given into the expected scope and the speculated limitations of the aforementioned vaccines.


Keywords:

SARS-CoV-2, Immunity, Vaccines, Safety Profile, Clinical Trials, Efficacy, Oxford, Pfizer, Moderna.




162888-403561-1-PB
.pdf
Download PDF • 1.10MB

5 views0 comments

Recent Posts

See All